GlassScriptPhysician profile
Christine H Mccarty
NPI 1437102878
$5,966.22
in general payments reported to CMS, 2019-2025
51 companies · $842 in 2025
The $842 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,569 · 2020: $1,333 · 2021: $1,625 · 2022: $170 · 2023: $61.67 · 2024: $367 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.39 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $547.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $410.95 | 2019-2025 | Datroway, Imfinzi |
| Incyte Corporation | $384.68 | 2020-2024 | Jakafi |
| Merck Sharp & Dohme LLC | $373.10 | 2019-2025 | Keytruda |
| Pfizer INC. | $365.51 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $356.89 | 2019-2025 | Opdivo |
| Eisai INC. | $334.34 | 2019-2025 | |
| Exelixis INC. | $281.29 | 2019-2021 | |
| Janssen Biotech, INC. | $259.53 | 2019-2021 | |
| Genentech USA, INC. | $193.55 | 2019-2020 | |
| Abbvie INC. | $146.00 | 2019-2021 | |
| Gilead Sciences, INC. | $144.44 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $144.41 | 2020-2025 | Jemperli |
| Novartis Pharmaceuticals Corporation | $137.88 | 2019-2025 | |
| Advanced Accelerator Applications | $124.83 | 2019 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.